Stay updated on Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial
Sign up to get notified when there's something new on the Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial page.

Latest updates to the Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded a note that recruitment is no longer being pursued and recorded a new record revision v3.6.0; the previous revision v3.5.5 entry was removed.SummaryDifference0.4%

- Check15 days agoChange DetectedThe study record history shows a new revision label v3.5.5 added, replacing the prior v3.5.4.SummaryDifference0.1%

- Check36 days agoChange DetectedA new page revision, v3.5.4, was added to the record history, replacing the previous v3.5.3 and signaling an update to the page's version metadata. This change reflects the latest build of the page rather than core content or functionality.SummaryDifference0.1%

- Check58 days agoChange DetectedThe update changes the displayed ClinicalTrials.gov page revision number from v3.5.2 to v3.5.3, reflecting a tooling/interface release rather than a modification to the trial record data.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision: v3.5.2 is now listed, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check72 days agoChange DetectedA new version entry was added to the Record History, reflecting updates to the study record such as status, design, eligibility, and contacts/locations.SummaryDifference0.1%

Stay in the know with updates to Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial page.